Health
CDC identifies possible ‘safety concern’ for certain people receiving COVID vaccines
The Facilities for Illness Management and Prevention (CDC) says {that a} preliminary COVID-19 vaccine “security sign” has been recognized and is investigating whether or not the Bivalent Pfizer-BioNTech vaccine creates an elevated threat of ischemic stroke in folks 65 and older.
Within the Friday assertion, the CDC mentioned that the preliminary sign hasn’t been recognized with the Bivalent Moderna COVID-19 vaccine.
“Following the provision and use of the up to date (bivalent) COVID-19 vaccines, CDC’s Vaccine Security Datalink (VSD), a close to real-time surveillance system, met the statistical standards to immediate extra investigation into whether or not there was a security concern for ischemic stroke in folks ages 65 and older who obtained the Pfizer-BioNTech COVID-19 Vaccine, Bivalent,” the CDC mentioned.
“Fast-response investigation of the sign within the VSD raised a query of whether or not folks 65 and older who’ve obtained the Pfizer-BioNTech COVID-19 Vaccine, Bivalent had been extra more likely to have an ischemic stroke within the 21 days following vaccination in contrast with days 22-44 following vaccination.”
In line with the CDC, an ischemic stroke “happens when blood clots or different particles block the blood vessels to the mind.”
COVID XBB.1.5 VARIANT NOW ACCOUNTS FOR 43% OF ALL US CASES, CDC SAYS
Within the assertion, the CDC identified that a big research of up to date bivalent vaccines from Pfizer-BioNTech “utilizing the Facilities for Medicare and Medicaid Providers database revealed no elevated threat of ischemic stroke.”
The company additionally mentioned that the Vaccine Adversarial Occasion Reporting System (VAERS) managed by CDC and FDA has not seen a rise in reporting of ischemic strokes following the up to date (bivalent) vaccine.
In a press release to Fox Information Digital, a spokesperson for Pfizer mentioned, “Pfizer and BioNTech have been made conscious of restricted stories of ischemic stroke which have been noticed within the CDC Vaccine Security DataLink (VSD) database in folks 65 and older following vaccination with the Omicron BA.4/BA.5-adapted bivalent COVID-19 Vaccine by Pfizer and BioNTech.”
COVID OMICRON SUBVARIANT XBB: WHY THE NUMBER OF CASES IS LIKELY FAR GREATER THAN REPORTED
“Neither Pfizer and BioNTech nor the CDC or the U.S. Meals and Drug Administration (FDA) have noticed related findings throughout quite a few different monitoring techniques within the U.S. and globally and there’s no proof to conclude that ischemic stroke is related to the usage of the businesses’ COVID-19 vaccines,” the spokesperson continued.
“In comparison with printed incidence charges of ischemic stroke on this older inhabitants, the businesses to this point have noticed a decrease variety of reported ischemic strokes following the vaccination with the Omicron BA.4/BA.5-adapted bivalent vaccine. The CDC continues to suggest vaccination with the Pfizer-BioNTech Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for all approved ages and indications.”
The CDC is not recommending a change in vaccine follow.
Fox Information medical contributor Dr. Marc Siegel mentioned that this is not “proof” of a hyperlink between the vaccine and strokes.
“This isn’t proof. That is that they see there could also be a hyperlink right here, they usually need to examine it, they usually’re attempting to be clear,” he mentioned.
Health
Study discovers 'trigger gene' in IBD as researchers look for drugs to prevent the bowel disease
Inflammatory bowel disease (IBD) — which includes Crohn’s disease and ulcerative colitis — affects around 3.1 million U.S. adults.
The disease can cause debilitating symptoms such as diarrhea, abdominal pain and cramping, blood in the stool and more.
Now, researchers at the U.K.’s Francis Crick Institute, working with UCL and Imperial College London, have discovered a genetic component — referred to as a “weak spot” in the DNA — that is present in 95% of those living with the disorder.
FIRST-EVER AUGMENTED REALITY ABDOMINAL SURGERY PERFORMED IN CHILE: ‘A REVOLUTION’
The study, published in the journal Nature earlier this month, identified a section of DNA that boosts the activity of a gene called ETS2.
ETS2 has been linked to inflammatory functions that increase the chances of IBD.
Rosario Ligresti, M.D., chief of the Division of Gastroenterology at Hackensack University Medical Center in New Jersey, was not involved in the research but called the findings “quite important.”
CANCER PREVENTION IN THE ESOPHAGUS COULD BE JUST A PILL AWAY, DOCTOR SAYS: ‘TREMENDOUS BENEFIT’
“The researchers finally showed that all autoimmune and inflammatory disease — including IBD — appear to be caused by a single gene, ETS2,” he told Fox News Digital.
“The research identified this gene as a central regulator of a type of inflammatory cell called the macrophage, which is the main inflammatory cell in all these processes.”
“IBD usually develops in young people and can cause severe symptoms that disrupt education, relationships, family life and employment.”
“The more the gene was ‘turned on’ or amplified, the greater the risk of inflammation. Without this gene, these cells do not ‘turn on’ and there is no IBD.”
While diet and stress have long been suspected to worsen IBD, the exact “‘molecular switch’ that activates inflammatory bowel disease has been unknown until now,” Ligresti noted.
“This discovery is so exciting and significant because it only gives us a better understanding of the inner workings of the disease, and it will allow researchers to adapt existing drugs to finally treat it,” added Ligresti.
The research team is now investigating drugs that could reduce the activity of the ETS2 gene, thus reducing the occurrence of IBD.
HERE’S WHY YOU’RE BLOATED — AND WHAT TO DO ABOUT THE COMMON DIGESTIVE CONDITION
They found that a group of existing anti-inflammatory medications called MEK inhibitors could do the trick.
“Although there have been many factors suggested as risks for IBD, there is currently no way to prevent the onset of IBD,” Ligresti said.
“We do know, however, that inflammatory pathways in the body are likely activated at least five years before the onset of symptoms of IBD.”
Ideally, he said, patients at increased risk could be given a drug during this window of time that could “nip IBD in the bud.”
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
While more research is needed to find ways to deliver these MEK inhibitors to the target cells, Ligresti noted that this finding opens a “tantalizing door” to the future of very effective therapies to “shut off” inflammatory bowel disease.
James Lee, group leader of the Genetic Mechanisms of Disease Laboratory at the Crick, who led the research, agreed that better treatments are “urgently needed.”
“IBD usually develops in young people and can cause severe symptoms that disrupt education, relationships, family life and employment,” Lee said in a Crick press release.
“Using genetics as a starting point, we’ve uncovered a pathway that appears to play a major role in IBD and other inflammatory diseases,” he said.
“Excitingly, we’ve shown that this can be targeted therapeutically, and we’re now working on how to ensure this approach is safe and effective for treating people in the future.”
Lauren Golightly, 27, was diagnosed with Crohn’s disease in 2018 after experiencing stomach cramps, bleeding and irregular bowel habits, according to the release.
“I’ve had a rocky road since diagnosis, with many hospital admissions, several different medications and even surgery to have a temporary stoma bag,” she said in the release.
For more Health articles, visit www.foxnews/health
“I still experience flare-ups and can still spend quite a bit of time in hospital.”
She also said, “Learning about this research is so exciting and encouraging. I am hopeful this could potentially make a difference for myself and so many other hundreds of thousands of people living with IBD.”
Fox News Digital reached out to the researchers for additional comment.
Health
‘Land of the Lost' 1974 Cast: What Happened to The Beloved Saturday Morning Stars?
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
Forgot your password?
Get back to the Sign In
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Health
More people sent to hospital as mushroom-infused 'microdosing' chocolate faces ongoing FDA probe
“Microdosing” chocolate bars designed to give consumers “peace of mind” have sent more and more people to hospitals, the Food and Drug Administration (FDA) recently reported.
The FDA published an initial advisory message about Diamond Shruumz, a company that produces “microdosing” chocolate bars and gummies, on June 7. At the time, six people who had consumed the products were hospitalized.
The FDA now reports that at least 10 people have been hospitalized after eating the products. An additional two people sought medical care but were not hospitalized.
“Do not eat, sell, or serve Diamond Shruumz-Brand Microdosing Chocolate Bars,” the FDA’s site warns.
MUSHROOM-INFUSED ‘MICRODOSING’ CHOCOLATE BARS ARE SENDING PEOPLE TO THE HOSPITAL, PROMPTING INVESTIGATION: FDA
“[The] FDA is working to determine the cause of these illnesses and is considering the appropriate next steps,” the statement added. “More information will be provided as it becomes available.”
The products are distributed nationally. The FDA’s website said hospitalizations were reported in Alabama, Kentucky, Missouri, Nevada, South Carolina and Pennsylvania. Four hospitalizations were recorded in Arizona, and two were reported in Indiana.
The consumers who ate the “microdosing” products experienced “severe” symptoms, officials reported.
STUDY FINDS EVIDENCE OF MICROPLASTICS IN BRAINS AND OTHER ORGANS
“People who became ill after eating Diamond Shruumz-brand Microdosing Chocolate Bars reported a variety of severe symptoms including seizures, central nervous system depression (loss of consciousness, confusion, sleepiness), agitation, abnormal heart rates, hyper/hypotension, nausea, and vomiting,” the FDA says.
“Microdosing” is when drug users take a minuscule amount of hallucinogenic drugs to increase creativity and boost their mood without having a psychedelic trip. Even though the Diamond Shruumz products are marketed as “microdosing,” the company reports that its products have no psilocybin in them.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“There is no presence of psilocybin, amanita or any scheduled drugs, ensuring a safe and enjoyable experience,” Diamond Shruumz’s website says. “Rest assured, our treats are not only free from psychedelic substances but our carefully crafted ingredients still offer an experience.”
“This allows you to indulge in a uniquely crafted blend designed for your pleasure and peace of mind.”
The FDA and Centers for Disease Control and Prevention are investigating the products. Fox News Digital reached out to Diamond Shruumz for comment but did not hear back.
For more Health articles, visit www.foxnews.com/health.
-
News1 week ago
Read Justice Clarence Thomas’s Financial Disclosures for 2023
-
Politics1 week ago
Newson, Dem leaders try to negotiate Prop 47 reform off California ballots, as GOP wants to let voters decide
-
World1 week ago
‘Bloody policies’: Bodies of 11 refugees and migrants recovered off Libya
-
Politics1 week ago
Gun group vows to 'defend' Trump's concealed carry license after conviction
-
Politics1 week ago
Should Trump have confidence in his lawyers? Legal experts weigh in
-
Politics6 days ago
GOP releases Jan. 6 clip of Pelosi saying 'I take responsibility' as she discussed National Guard absence
-
Movie Reviews1 week ago
‘Darkest Miriam’ Review: Britt Lower in a Marvel of a Drama About a Young Librarian’s Loves and Fears
-
World1 week ago
Orban party loses major support in Hungary's EU election